Adamas Reports First Quarter 2018 Financial Results GOCOVRI™ (amantadine) extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions Received positive feedback from the U.S....

Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy EMERYVILLE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive topline data from the Phase 1b clinical trial of ADS-4101 (lacosamide)...

Adamas to Present at Two Upcoming Investor Conferences EMERYVILLE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company’s Chairman and Chief Executive Officer, is...

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy -- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study...

Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in...